Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202
(NASDAQ: CNTX) Delayed: 0.37 --0 (-0%)
Previous Close $0.37    52 Week High $ 
Open $0.38    52 Week Low $ 
Day High $0.39    P/E N/A 
Day Low $0.36    EPS $ 
Volume 745,001